Form 4: Voyager Therapeutics Executive Sells Shares to Cover Tax Obligations

Todd Alfred Carter, Chief Scientific Officer of Voyager Therapeutics, sold 5,413 shares of common stock to cover tax obligations related to vesting restricted stock units.

Summary

• On February 11, 2025, Todd Alfred Carter, the Chief Scientific Officer of Voyager Therapeutics, sold 5,413 shares of the company's common stock.
• The sale was executed to cover tax withholding obligations associated with the vesting of restricted stock units on February 9, 2025.
• The shares were sold at a weighted average price of $4.45, with individual transactions ranging from $4.13 to $5.00.
• Following the transaction, Carter directly owns 81,023 shares of Voyager Therapeutics common stock.

Sentiment

Score: 5

Explanation: This is a neutral event. It's a routine transaction to cover tax obligations and doesn't necessarily reflect a positive or negative outlook on the company.

Industry Context

This is a routine Form 4 filing, indicating an insider transaction related to tax obligations. It's common for executives to sell shares to cover taxes when restricted stock units vest.

Stakeholder Impact

• The sale of shares by an executive could have a minor impact on shareholder sentiment, but is unlikely to be significant given the reason for the sale.

Key Dates